Yes-associated protein in the liver: Regulation of hepatic development, repair, cell fate determination and tumorigenesis

Digestive and Liver Disease

Volumn 47, Issue 10, 2015, Pages 826-835

  Nguyen, Quy ^a   Anders, Robert A ^d   Alpini, Gianfranco ^a,b,c   Bai, Haibo ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Digestive Disease Research Center   (United States)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hippo signalling pathway; Liver; YAP

Indexed keywords

LIVER PROTEIN; MESSENGER RNA; PROTEIN KINASE YES; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

CELL FATE; ENZYME ACTIVITY; GENE DELETION; HOMEOSTASIS; HUMAN; KNOCKOUT MOUSE; LETHALITY; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL; LIVER DEVELOPMENT; LIVER DISEASE; LIVER INJURY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STABILITY; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; TISSUE REPAIR; TRANSCRIPTION REGULATION; ANIMAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION; GENETICS; LIVER; LIVER TUMOR; METABOLISM; MOUSE; PHYSIOLOGY; RAT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; HOMEOSTASIS; HUMANS; LIVER; LIVER NEOPLASMS; MICE; PHOSPHOPROTEINS; RATS;

EID: 84942194781     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2015.05.011     Document Type: Review

References (111)

1. Sudol M. Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. Oncogene 1994, 9:2145-2152.
2. Huang J., Wu S., Barrera J., et al. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell 2005, 122:421-434.
3. Lai Z.C., Wei X., Shimizu T., et al. Control of cell proliferation and apoptosis by mob as tumor suppressor, mats. Cell 2005, 120:675-685.
4. Wu S., Huang J., Dong J., et al. Hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell 2003, 114:445-456.
5. Pan D. Hippo signaling in organ size control. Genes & Development 2007, 21:886-897.
6. Pan D. The hippo signaling pathway in development and cancer. Developmental Cell 2010, 19:491-505.
7. Tao W., Zhang S., Turenchalk G.S., et al. Human homologue of the Drosophila melanogaster lats tumour suppressor modulates CDC2 activity. Nature Genetics 1999, 21:177-181.
8. Yin F., Yu J., Zheng Y., et al. Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell 2013, 154:1342-1355.
9. Dong J., Feldmann G., Huang J., et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007, 130:1120-1133.
10. Vassilev A., Kaneko K.J., Shu H., et al. TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes & Development 2001, 15:1229-1241.
11. Liu-Chittenden Y., Huang B., Shim J.S., et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes & Development 2012, 26:1300-1305.
12. Koontz L.M., Liu-Chittenden Y., Yin F., et al. The Hippo effector Yorkie controls normal tissue growth by antagonizing scalloped-mediated default repression. Developmental Cell 2013, 25:388-401.
13. Michalopoulos G.K., DeFrances M.C. Liver regeneration. Science 1997, 276:60-66.
14. Morin-Kensicki E.M., Boone B.N., Howell M., et al. Defects in yolk sac vasculogenesis, chorioallantoic fusion, and embryonic axis elongation in mice with targeted disruption of Yap65. Molecular and Cellular Biology 2006, 26:77-87.
15. Zhang N., Bai H., David K.K., et al. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Developmental Cell 2010, 19:27-38.
16. Geisler F., Nagl F., Mazur P.K., et al. Liver-specific inactivation of Notch2, but not Notch1, compromises intrahepatic bile duct development in mice. Hepatology 2008, 48:607-616.
17. Xu X., Kobayashi S., Qiao W., et al. Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. Journal of Clinical Investigation 2006, 116:1843-1852.
18. Lemaigre F.P. Development of the biliary tract. Mechanisms of Development 2003, 120:81-87.
19. Zong Y., Stanger B.Z. Molecular mechanisms of liver and bile duct development. Wiley Interdisciplinary Reviews Developmental Biology 2012, 1:643-655.
20. Hamaratoglu F., Willecke M., Kango-Singh M., et al. The tumour-suppressor genes NF2/Merlin and expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nature Cell Biology 2006, 8:27-36.
21. Yu J., Poulton J., Huang Y.C., et al. The hippo pathway promotes Notch signaling in regulation of cell differentiation, proliferation, and oocyte polarity. PLoS ONE 2008, 3:e1761.
22. Chen H.J., Wang C.M., Wang T.W., et al. The Hippo pathway controls polar cell fate through Notch signaling during Drosophila oogenesis. Developmental Biology 2011, 357:370-379.
23. Tschaharganeh D.F., Chen X., Latzko P., et al. Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology 2013, 144:1530-1542. e12.
24. Yimlamai D., Christodoulou C., Galli G.G., et al. Hippo pathway activity influences liver cell fate. Cell 2014, 157:1324-1338.
25. McCright B., Lozier J., Gridley T. A mouse model of Alagille syndrome: Notch2 as a genetic modifier of Jag1 haploinsufficiency. Development 2002, 129:1075-1082.
26. Bai H., Zhang N., Xu Y., et al. Yes-associated protein regulates the hepatic response after bile duct ligation. Hepatology 2012, 56:1097-1107.
27. Benhamouche S., Curto M., Saotome I., et al. Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes & Development 2010, 24:1718-1730.
28. Georgiev P., Jochum W., Heinrich S., et al. Characterization of time-related changes after experimental bile duct ligation. British Journal of Surgery 2008, 95:646-656.
29. Apte U., Gkretsi V., Bowen W.C., et al. Enhanced liver regeneration following changes induced by hepatocyte-specific genetic ablation of integrin-linked kinase. Hepatology 2009, 50:844-851.
30. Wang C., Zhang L., He Q., et al. Differences in Yes-associated protein and mRNA levels in regenerating liver and hepatocellular carcinoma. Molecular Medicine Reports 2012, 5:410-414.
31. Wu H., Xiao Y., Zhang S., et al. The Ets transcription factor GABP is a component of the hippo pathway essential for growth and antioxidant defense. Cell Reports 2013, 3:1663-1677.
32. Michalopoulos G.K., Barua L., Bowen W.C. Transdifferentiation of rat hepatocytes into biliary cells after bile duct ligation and toxic biliary injury. Hepatology 2005, 41:535-544.
33. Greenbaum L.E. The ductal plate: a source of progenitors and hepatocytes in the adult liver. Gastroenterology 2011, 141:1152-1155.
34. Fitamant J., Kottakis F., Benhamouche S., et al. YAP inhibition restores hepatocyte differentiation in advanced HCC, leading to tumor regression. Cell Reports 2015, 10:1692-1707.
35. Cai J., Zhang N., Zheng Y., et al. The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes & Development 2010, 24:2383-2388.
36. Barry E.R., Morikawa T., Butler B.L., et al. Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature 2013, 493:106-110.
37. George N.M., Day C.E., Boerner B.P., et al. Hippo signaling regulates pancreas development through inactivation of Yap. Molecular and Cellular Biology 2012, 32:5116-5128.
38. Gao T., Zhou D., Yang C., et al. Hippo signaling regulates differentiation and maintenance in the exocrine pancreas. Gastroenterology 2013, 144:1543-1553. e1.
39. Yu F.X., Meng Z., Plouffe S.W., et al. Hippo pathway regulation of gastrointestinal tissues. Annual Review of Physiology 2015, 77:201-227.
40. Zender L., Spector M.S., Xue W., et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006, 125:1253-1267.
41. Imoto I., Yang Z.Q., Pimkhaokham A., et al. Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. Cancer Research 2001, 61:6629-6634.
42. Dai Z., Zhu W.G., Morrison C.D., et al. A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes. Human Molecular Genetics 2003, 12:791-801.
43. Bashyam M.D., Bair R., Kim Y.H., et al. Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer. Neoplasia 2005, 7:556-562.
44. Snijders A.M., Schmidt B.L., Fridlyand J., et al. Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma. Oncogene 2005, 24:4232-4242.
45. Zhou D., Medoff B.D., Chen L., et al. The Nore1B/Mst1 complex restrains antigen receptor-induced proliferation of naive T cells. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:20321-20326.
46. Dan I., Watanabe N.M., Kusumi A. The Ste20 group kinases as regulators of MAP kinase cascades. Trends in Cell Biology 2001, 11:220-230.
47. Zhou D., Conrad C., Xia F., et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 2009, 16:425-438.
48. Song H., Mak K.K., Topol L., et al. Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:1431-1436.
49. Lee K.P., Lee J.H., Kim T.S., et al. The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:8248-8253.
50. Lu L., Li Y., Kim S.M., et al. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:1437-1442.
51. Tao J., Calvisi D.F., Ranganathan S., et al. Activation of beta-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice. Gastroenterology 2014, 147:690-701.
52. Kowalik M.A., Saliba C., Pibiri M., et al. Yes-associated protein regulation of adaptive liver enlargement and hepatocellular carcinoma development in mice. Hepatology 2011, 53:2086-2096.
53. Perra A., Kowalik M.A., Ghiso E., et al. YAP activation is an early event and a potential therapeutic target in liver cancer development. Journal of Hepatology 2014, 61:1088-1096.
54. Zhao B., Wei X., Li W., et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes & Development 2007, 21:2747-2761.
55. Xu M.Z., Yao T.J., Lee N.P., et al. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 2009, 115:4576-4585.
56. Bai H., Gayyed M.F., Lam-Himlin D.M., et al. Expression of Yes-associated protein modulates survivin expression in primary liver malignancies. Human Pathology 2012, 43:1376-1385.
57. Li H., Wolfe A., Septer S., et al. Deregulation of Hippo kinase signalling in human hepatic malignancies. Liver International: Official Journal of the International Association for the Study of the Liver 2012, 32:38-47.
58. Zhang T., Zhang J., You X., et al. Hepatitis B virus X protein modulates oncogene Yes-associated protein by CREB to promote growth of hepatoma cells. Hepatology 2012, 56:2051-2059.
59. Ahn E.Y., Kim J.S., Kim G.J., et al. RASSF1A-mediated regulation of AREG via the Hippo pathway in hepatocellular carcinoma. Molecular Cancer Research: MCR 2013, 11:748-758.
60. Bai N., Zhang C., Liang N., et al. Yes-associated protein (YAP) increases chemosensitivity of hepatocellular carcinoma cells by modulation of p53. Cancer Biology & Therapy 2013, 14:511-520.
61. Xu M.Z., Chan S.W., Liu A.M., et al. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene 2011, 30:1229-1240.
62. Gurda G.T., Zhu Q., Bai H., et al. The use of Yes-associated protein expression in the diagnosis of persistent neonatal cholestatic liver disease. Human Pathology 2014, 45:1057-1064.
63. Anakk S., Bhosale M., Schmidt V.A., et al. Bile acids activate YAP to promote liver carcinogenesis. Cell Reports 2013, 5:1060-1069.
64. Chen C.L., Tsukamoto H., Liu J.C., et al. Reciprocal regulation by TLR4 and TGF-beta in tumor-initiating stem-like cells. Journal of Clinical Investigation 2013, 123:2832-2849.
65. Wang J., Ma L., Weng W., et al. Mutual interaction between YAP and CREB promotes tumorigenesis in liver cancer. Hepatology 2013, 58:1011-1020.
66. Urtasun R., Latasa M.U., Demartis M.I., et al. Connective tissue growth factor autocriny in human hepatocellular carcinoma: oncogenic role and regulation by epidermal growth factor receptor/yes-associated protein-mediated activation. Hepatology 2011, 54:2149-2158.
67. Hughes C.M., Rozenblatt-Rosen O., Milne T.A., et al. Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Molecular Cell 2004, 13:587-597.
68. Xu B., Li S.H., Zheng R., et al. Menin promotes hepatocellular carcinogenesis and epigenetically up-regulates Yap1 transcription. Proceedings of the National Academy of Sciences of the United States of America 2013, 110:17480-17485.
69. Liu A.M., Poon R.T., Luk J.M. MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochemical and Biophysical Research Communications 2010, 394:623-627.
70. Kuroda S., Fukata M., Nakagawa M., et al. Role of IQGAP1, a target of the small GTPases Cdc42 and Rac1, in regulation of E-cadherin-mediated cell-cell adhesion. Science 1998, 281:832-835.
71. Kim N.G., Koh E., Chen X., et al. E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:11930-11935.
72. Dupont S., Morsut L., Aragona M., et al. Role of YAP/TAZ in mechanotransduction. Nature 2011, 474:179-183.
73. Calvo F., Ege N., Grande-Garcia A., et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nature Cell Biology 2013, 15:637-646.
74. Zhao B., Li L., Wang L., et al. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes & Development 2012, 26:54-68.
75. Aragona M., Panciera T., Manfrin A., et al. A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. Cell 2013, 154:1047-1059.
76. Fletcher G.C., Elbediwy A., Khanal I., et al. The spectrin cytoskeleton regulates the Hippo signalling pathway. The EMBO Journal 2015, 34:940-954.
77. Deng H., Wang W., Yu J., et al. Spectrin regulates Hippo signaling by modulating cortical actomyosin activity. Elife 2015, 4:e06567.
78. DeRan M., Yang J., Shen C.H., et al. Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein. Cell Reports 2014, 9:495-503.
79. Mo J.S., Meng Z., Kim Y.C., et al. Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway. Nature Cell Biology 2015, 17:500-510.
80. Yu F.X., Guan K.L. The Hippo pathway: regulators and regulations. Genes & Development 2013, 27:355-371.
81. DuPont C.M., Coppola J.J., Kaercher R.M., et al. Impaired trace fear conditioning and diminished ERK1/2 phosphorylation in the dorsal hippocampus of adult rats administered alcohol as neonates. Behavioral Neuroscience 2014, 128:187-198.
82. Miller E., Yang J., DeRan M., et al. Identification of serum-derived sphingosine-1-phosphate as a small molecule regulator of YAP. Chemistry & Biology 2012, 19:955-962.
83. Yu F.X., Zhao B., Panupinthu N., et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 2012, 150:780-791.
84. Zhao B., Li L., Tumaneng K., et al. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes & Development 2010, 24:72-85.
85. Strano S., Munarriz E., Rossi M., et al. Physical interaction with Yes-associated protein enhances p73 transcriptional activity. Journal of Biological Chemistry 2001, 276:15164-15173.
86. Yagi R., Chen L.F., Shigesada K., et al. A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator. The EMBO Journal 1999, 18:2551-2562.
87. Ota M., Sasaki H. Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling. Development 2008, 135:4059-4069.
88. Zhao B., Ye X., Yu J., et al. TEAD mediates YAP-dependent gene induction and growth control. Genes & Development 2008, 22:1962-1971.
89. Sawada A., Kiyonari H., Ukita K., et al. Redundant roles of Tead1 and Tead2 in notochord development and the regulation of cell proliferation and survival. Molecular and Cellular Biology 2008, 28:3177-3189.
90. Zhang J., Ji J.Y., Yu M., et al. YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nature Cell Biology 2009, 11:1444-1450.
91. Shimomura T., Miyamura N., Hata S., et al. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity. Biochemical and Biophysical Research Communications 2014, 443:917-923.
92. Xiao W., Wang J., Ou C., et al. Mutual interaction between YAP and c-Myc is critical for carcinogenesis in liver cancer. Biochemical and Biophysical Research Communications 2013, 439:167-172.
93. Guo T., Lu Y., Li P., et al. A novel partner of Scalloped regulates Hippo signaling via antagonizing Scalloped-Yorkie activity. Cell Research 2013, 23:1201-1214.
94. Jiao S., Wang H., Shi Z., et al. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell 2014, 25:166-180.
95. Serrano I., McDonald P.C., Lock F., et al. Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase. Nature Communications 2013, 4:2976.
96. Wada K., Itoga K., Okano T., et al. Hippo pathway regulation by cell morphology and stress fibers. Development 2011, 138:3907-3914.
97. Camargo F.D., Gokhale S., Johnnidis J.B., et al. YAP1 increases organ size and expands undifferentiated progenitor cells. Current Biology: CB 2007, 17:2054-2060.
98. Saburi S., Hester I., Fischer E., et al. Loss of Fat4 disrupts PCP signaling and oriented cell division and leads to cystic kidney disease. Nature Genetics 2008, 40:1010-1015.
99. Bossuyt W., Chen C.L., Chen Q., et al. An evolutionary shift in the regulation of the Hippo pathway between mice and flies. Oncogene 2014, 33:1218-1228.
100. Tommasi S., Dammann R., Zhang Z., et al. Tumor susceptibility of Rassf1a knockout mice. Cancer Research 2005, 65:92-98.
101. van der Weyden L., Tachibana K.K., Gonzalez M.A., et al. The RASSF1A isoform of RASSF1 promotes microtubule stability and suppresses tumorigenesis. Molecular and Cellular Biology 2005, 25:8356-8367.
102. Park J., Kang S.I., Lee S.Y., et al. Tumor suppressor ras association domain family 5 (RASSF5/NORE1) mediates death receptor ligand-induced apoptosis. Journal of Biological Chemistry 2010, 285:35029-35038.
103. McClatchey A.I., Saotome I., Ramesh V., et al. The Nf2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation. Genes & Development 1997, 11:1253-1265.
104. McClatchey A.I., Saotome I., Mercer K., et al. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes & Development 1998, 12:1121-1133.
105. Oh S., Lee D., Kim T., et al. Crucial role for Mst1 and Mst2 kinases in early embryonic development of the mouse. Molecular and Cellular Biology 2009, 29:6309-6320.
106. Lee J.H., Kim T.S., Yang T.H., et al. A crucial role of WW45 in developing epithelial tissues in the mouse. The EMBO Journal 2008, 27:1231-1242.
107. St John M.A., Tao W., Fei X., et al. Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction. Nature Genetics 1999, 21:182-186.
108. McPherson J.P., Tamblyn L., Elia A., et al. Lats2/Kpm is required for embryonic development, proliferation control and genomic integrity. The EMBO Journal 2004, 23:3677-3688.
109. Nishio M., Hamada K., Kawahara K., et al. Cancer susceptibility and embryonic lethality in Mob1a/1b double-mutant mice. Journal of Clinical Investigation 2012, 122:4505-4518.
110. Hossain Z., Ali S.M., Ko H.L., et al. Glomerulocystic kidney disease in mice with a targeted inactivation of Wwtr1. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:1631-1636.
111. Yi C., Shen Z., Stemmer-Rachamimov A., et al. The p130 isoform of angiomotin is required for Yap-mediated hepatic epithelial cell proliferation and tumorigenesis. Science Signaling 2013, 6:ra77.